

**Monoclonal Anti- CK19 / CYFRA21-1 (Detection Ab)****Catalog#** BDA1012**Lot #** Check on the product label**Size** 1mg**Isotype** IgG1**Clone #** C4**Host** Mouse**Reactivity**

Human

**Product Form** Liquid**Purification & Buffer**

Protein A or G purified and supplied in 0.01 M PBS (pH7.4) &amp; 0.15 M NaCl without preservative.

**Purity** >95% by HPLC & SDS-PAGE**Immunogen**

40 KDa of Keratin 19 protein.

**Specificity** It specifically recognize the human CK19 / CYFRA21-1, and may cross react with CK20, CK8 & CK18.**Recommend Application**

Western Blot

ELISA

Chemiluminescent immunoassay, CLIA

Other applications have not been tested.

The optimal dilutions should be determined by end user.

**Matched antibody pair**

Capture Ab: CYFRA21-1 mAb (clone # D5)

Detection Ab: CYFRA21-1 mAb (clone # C4)

**Storage Instruction**

Aliquot and store at -20°C for long term (at least one year).

Avoid repeated freeze and thaw cycles.

**Background**

Keratin, type I cytoskeletal 19 also known as cytokeratin-19 (CK-19) or keratin-19 (K19) is a 40 kDa protein that in humans is encoded by the KRT19 gene. KRT19 is also known as Cyfra 21-1. The usefulness of serum CYFRA 21-1 (cytokeratin-19 fragments) in monitoring the recurrence of breast cancer and in evaluating therapeutic effects. Serum CYFRA 21-1 may be a reliable marker of recurrence or therapeutic efficacy. The serum level of Cyfra21-1 was a useful biomarker for diagnosis of nonsmall cell lung cancer (NSCLC) as well. The serum cytokeratin 19 fragment 21.1 (CYFRA21-1) level was elevated in nasopharyngeal carcinoma (NPC) and can function as a biomarker for detection and monitoring of NPC. After analyzing NPC group and healthy control group, Song XM et al concluded that the serum CYFRA21-1 level could be a reliable and effective biomarker for the detection and monitoring of NPC tumor progression.

**Reference**

1. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW (July 2006). "New consensus nomenclature for mammalian keratins". *J Cell Biol* 174 (2): 169 - 74.
2. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. *Br J Cancer*. 2004 Aug 31;91(5):873-8.
3. Cui C, Sun X, Zhang J, Han D, Gu J. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis. *J Cancer Res Ther*. 2014 Nov;10 Suppl:C131-4.
4. Song XM, Wang SZ, Wang ZJ, Cao WJ, L J, Chen F. Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. *Neoplasma*. 2015;62(1):124-9.

FOR RESEARCH USE ONLY, NOT FOR DIAGNOSTIC AND CLINICAL USE.

Chongqing Biospes Co., Ltd Tel: +86-23-67567091 Fax: +86-23-67745923

7F, Bldg B, High-tech Venture Park, # 107 Erlang Chuangye Rd, Jiulongpo District, Chongqing, 400039, China

[www.biospes.com](http://www.biospes.com)